- ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)
- ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024
- ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
- ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award
- ChromaDex Corporation Reports First Quarter 2024 Financial Results
- ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement
- ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®
- ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
- ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market
- ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program
More ▼
Key statistics
On Friday, Chromadex Corp (CDXC:NAQ) closed at 3.20, -31.18% below its 52-week high of 4.65, set on Apr 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.10 |
---|---|
High | 3.49 |
Low | 3.09 |
Bid | 3.23 |
Offer | 3.37 |
Previous close | 2.86 |
Average volume | 345.74k |
---|---|
Shares outstanding | 75.54m |
Free float | 48.51m |
P/E (TTM) | -- |
Market cap | 216.04m USD |
EPS (TTM) | -0.047 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 21:00 BST.
More ▼